Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

NCT03097107 is registered in ClinicalTrials.gov with Zydus Therapeutics Inc. as lead sponsor.

NCT NCT03097107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03097107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
Lead sponsor
Zydus Therapeutics Inc.
Phase
Phase 2
Overall status
Suspended
Start date
April 6, 2017
Completion date
January 31, 2024
Enrollment
124 (estimated)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias